Last reviewed · How we verify
Besifloxacin 0.6% ophthalmic suspension
Besifloxacin 0.6% ophthalmic suspension is a Small molecule drug developed by Johns Hopkins University. It is currently FDA-approved. Also known as: Besivance.
At a glance
| Generic name | Besifloxacin 0.6% ophthalmic suspension |
|---|---|
| Also known as | Besivance |
| Sponsor | Johns Hopkins University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Besifloxacin in Bacterial Keratitis (NA)
- Effect of Topical Besifloxacin on Ocular Surface Bacterial Microbiota Prior to Cataract Surgery (PHASE1)
- Study of Ocular Penetration of Topically Administered Fluoroquinolones (PHASE4)
- Safety and Efficacy Study of Besivance™ for Treatment of Congenital Nasolacrimal Duct Obstruction in Children (PHASE1)
- A Comparison of Three Fluoroquinolone Topical Eyedrops in the Treatment of Infectious Corneal Ulcers. (PHASE2)
- A Study to Investigate the Safety and Efficacy of BOL-303224 in the Treatment of Bacterial Conjunctivitis (PHASE3)
- A Study to Determine if 0.6% ISV-403 is Safe and Effective in the Treatment of Bacterial Conjunctivitis. (PHASE3)
- Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% in the Treatment of Bacterial Conjunctivitis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Besifloxacin 0.6% ophthalmic suspension CI brief — competitive landscape report
- Besifloxacin 0.6% ophthalmic suspension updates RSS · CI watch RSS
- Johns Hopkins University portfolio CI
Frequently asked questions about Besifloxacin 0.6% ophthalmic suspension
What is Besifloxacin 0.6% ophthalmic suspension?
Besifloxacin 0.6% ophthalmic suspension is a Small molecule drug developed by Johns Hopkins University.
Who makes Besifloxacin 0.6% ophthalmic suspension?
Besifloxacin 0.6% ophthalmic suspension is developed and marketed by Johns Hopkins University (see full Johns Hopkins University pipeline at /company/johns-hopkins-university).
Is Besifloxacin 0.6% ophthalmic suspension also known as anything else?
Besifloxacin 0.6% ophthalmic suspension is also known as Besivance.
What development phase is Besifloxacin 0.6% ophthalmic suspension in?
Besifloxacin 0.6% ophthalmic suspension is FDA-approved (marketed).
Related
- Manufacturer: Johns Hopkins University — full pipeline
- Also known as: Besivance
- Compare: Besifloxacin 0.6% ophthalmic suspension vs similar drugs
- Pricing: Besifloxacin 0.6% ophthalmic suspension cost, discount & access